DR. MICHAEL B.A. OLDSTONE, M.D.
Medical Practice at Exchange Pl, La Jolla, CA
License number
California G11785
Category
Medical Practice
Type
Health Educator
Address
Address
7710 Exchange Pl, La Jolla, CA 92037
Phone
(858) 454-2394
(858) 784-8054
(858) 784-8054
Professional information
Dr. Michael B Oldstone, La Jolla CA - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
10550 N Torrey Pines Rd, La Jolla 92037
(858) 784-1000 (Phone)
(858) 784-1000 (Phone)
Languages:
English
Education:
Medical School
University of Maryland At Baltimore / Professional Schools
Graduated: 1961
University of Maryland At Baltimore / Professional Schools
Graduated: 1961
Arenavirus Receptor And Methods Of Use
US Patent:
6083911, Jul 4, 2000
Filed:
Dec 10, 1998
Appl. No.:
9/208707
Inventors:
Kevin P. Campbell - Iowa City IA
Michael Henry - Iowa City IA
Hiroki Yamada - Iowa City IA
Roger Williamson - Iowa City IA
Wei Cao - San Diego CA
Michael Oldstone - La Jolla CA
Michael Henry - Iowa City IA
Hiroki Yamada - Iowa City IA
Roger Williamson - Iowa City IA
Wei Cao - San Diego CA
Michael Oldstone - La Jolla CA
Assignee:
University of Iowa Research Foundation - Iowa City IA
International Classification:
A61K 3534, A61K 3816
US Classification:
514 8
Abstract:
Disclosed is a method for inhibiting the binding of an arenavirus to a cellular receptor. The method involves providing, in soluble form, a reagent comprising. alpha. -dystroglycan or a portion thereof, the reagent being characterized by the ability to bind to the arenavirus thereby inhibiting the binding of the arenavirus to the cellular receptor. The reagent is contacted with an arenavirus particle prior to infection of a cell by the arenavirus particle. Also disclosed are methods for treating an arenavirus infection in a patient and preventing an arenavirus infection in an individual at risk. These methods involve providing a therapeutic composition comprising. alpha. -dystroglycan or a portion thereof which is characterized by the ability to bind to arenaviruses, thereby inhibiting the binding of arenaviruses to a cellular receptor; and administering the composition to the patient or individual at risk. Arenaviruses to which the methods of the present invention apply include, without limitation, Lymphocyte Choriomeningitis Virus, Lassa fever virus, Mobala, and Oliveros. In another aspect, the disclosure relates to an embryonic stem cell line, and cells derived therefrom, which is homozygous for a disrupted dystroglycan gene, wherein the disruption prevents the synthesis of functional dystroglycan in the cells.
Protection And Treatment Against Influenza Infection
US Patent:
2013020, Aug 8, 2013
Filed:
Feb 7, 2013
Appl. No.:
13/761922
Inventors:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA, US
THE SCRIPPS RESEARCH INSTITUTE - La Jolla CA, US
Robert Krug - Austin TX, US
Meghana Malur - Austin TX, US
Michael Oldstone - La Jolla CA, US
John Teijaro - La Jolla CA, US
THE SCRIPPS RESEARCH INSTITUTE - La Jolla CA, US
Robert Krug - Austin TX, US
Meghana Malur - Austin TX, US
Michael Oldstone - La Jolla CA, US
John Teijaro - La Jolla CA, US
Assignee:
THE SCRIPPS RESEARCH INSTITUTE - La Jolla CA
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K 31/438, A61K 45/00, A61K 31/44
US Classification:
514278, 514357
Abstract:
Method and composition for protection and treatment against influenza viral infection by modulating the activity of at least one essential host signaling pathways, including the Hedgehog (Hh), the Bone Morphogenetic Protein (BMP), the Notch (N) signaling pathways or combinations thereof, which activity is altered by the viral protein NS1. The method and composition comprise use of a compound that modulates at least one of these essential host signaling pathways for preventing or controlling symptoms associated with influenza viral infection. The method or composition can also be used either alone or in combination with other therapeutic agents for treating or protecting against influenza infection, and associated syndromes.
Combination Therapy To Treat Persistent Viral Infections
US Patent:
2011000, Jan 13, 2011
Filed:
Oct 29, 2008
Appl. No.:
12/739637
Inventors:
David Brooks - San Diego CA, US
Michael B.A. Oldstone - La Jolla CA, US
Michael B.A. Oldstone - La Jolla CA, US
Assignee:
THE SCRIPPS RESEARCH INSTITUTE - La Jolla CA
International Classification:
A61K 39/395, A61K 39/00, A61P 37/04, A61P 31/12
US Classification:
4241331, 4241841, 4241451
Abstract:
The present invention pres ides combination therapies to treat persistent viral infections. In particular, combinations of vaccines and IL-10 or IL-10 receptor (IL-10R) antagonists to clear such infections are provided.